The Business Journals

Generate:Biomedicines eyes public markets as AI drug advances to late-stage trials

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
pharmaphorum

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
InfoWorld

JDK 26: The new features in Java 26

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...